Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025) Multiple Secondary Symptom Endpoints Met, Statistical...

Related Keywords

United States ,American , ,Securities Exchange ,Company To Host Conference Call ,Palatin Technologies Inc ,Prnewswire Palatin Technologies Inc ,Intent To Treat Analysis ,Co Primary Symptom Endpoint Met ,Statistical Significance ,Secondary Symptom Endpoints Met ,Co Primary Sign Endpoint ,Secondary Sign Endpoints Not ,Superiority Over Vehicle ,Multiple Sign ,Discussions Planned ,Regulatory Approval ,Host Conference Call ,Conference Call ,Eastern Time ,Participant Access Code ,Replay Passcode ,Dry Eye Disease ,Market Scope ,Eye Product Market Review ,Melanocortin Receptor Agonists ,Palatin Technologies ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,